Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Madrigal Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (113)	7/20/2019 1:51:00 AM
From: Miljenko Zuanic	Respond to of 138

<5.Biopsy-proven NASH (Baseline liver biopsy) based on a liver biopsy obtained within 24 weeks before anticipated date of randomization (if the biopsy is deemed acceptable for interpretation by the central reader) with fibrosis stage 1A, 1B, 2, or 3 on liver biopsy and NAS of = 4 with a score of at least 1 in each of the following NAS components: > Stage 1A/B was already part of the enrolment criteria. First 900 will have 450 of the F3, so I am not much concerned with power (80 and 100 mg seems almost as one)...but enrolment center(s) is something that I do not understand well. Central CRO, that control all centers? Further, as mentioned early, exclusion of the T2D on GLP-1 is much more disappointment than anything else.